特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
955308

慢性特発性蕁麻疹 (CSU) 治療薬 - 市場考察、疫学、市場予測:2030年

Chronic Spontaneous Urticaria - Market Insights, Epidemiology, and Market Forecast - 2030

出版日: | 発行: DelveInsight Business Research LLP | ページ情報: 英文 188 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.70円
慢性特発性蕁麻疹 (CSU) 治療薬 - 市場考察、疫学、市場予測:2030年
出版日: 2020年08月01日
発行: DelveInsight Business Research LLP
ページ情報: 英文 188 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、慢性特発性蕁麻疹 (CSU) 治療薬について調査分析し、過去・将来の疫学、米国・欧州5ヶ国 (ドイツ、スペイン、イタリア、フランス、英国) ・日本の市場動向に焦点を当てて、現在の治療法、新薬、市場規模などについて、体系的な情報を提供しています。

目次

第1章 主な考察

第2章 エグゼクティブサマリー

第3章 組織

第4章 疫学と市場調査手法

第5章 慢性特発性蕁麻疹 (CSU) :市場概要

  • 2017年のCSUの市場シェア分布
  • 2030年のCSUの市場シェア分布

第6章 慢性特発性蕁麻疹 (CSU) :市場概要

  • イントロダクション
  • 分類
  • 原因
  • 兆候と症状
  • 臨床所見
  • 病因
  • 診断
  • 治療

第7章 疫学と患者集団

  • 主な調査結果
  • 主要7ヶ国のCSUの症例
  • 米国
    • 前提条件と根拠
    • 有病総数
    • 性別
    • 年齢別
  • 欧州5ヶ国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 英国
  • 日本

第8章 現在の治療法

第9章 アンメットニーズ

第10章 上市薬

  • XOLAIR:Roche/Novartis

第11章 新薬

  • Dupilumab:Sanofi/Regeneron
  • Ligelizumab:Novartis Pharmaceuticals
  • Benralizumab:AstraZeneca
  • Fenebrutinib:Genentech, Inc.
  • KPL-716:Kiniksa Pharmaceuticals, Ltd.
  • LOU064:Novartis Pharmaceuticals
  • UB-221:United BioPharma
  • LY3454738:Eli Lilly and Company
  • Mepolizumab:GlaxoSmithKline
  • AK002:Allakos

第12章 慢性特発性蕁麻疹 (CSU) :主要7ヶ国市場分析

  • 主な調査結果
  • 市場規模

第13章 主要7ヶ国市場の見通し

第14章 米国の市場規模

第15章 市場促進要因

第16章 市場の障壁

第17章 SWOT分析

第18章 市場参入

第19章 ケーススタディ

第20章 KOLの見解

第21章 付録

第22章 DelveInsightのサービス内容

第23章 免責事項

第24章 DelveInsightについて

図表

List of Tables

  • Table 1: Classification of Urticaria
  • Table 2: Etiology
  • Table 3: Urticaria-Associated History And Physical Examination Findings with Possible Etiologies
  • Table 4: Urticaria-Associated History And Physical Examination Findings with Possible Etiologies
  • Table 5: Conditions That May Be Confused with Urticaria
  • Table 6: Treatment Algorithm For Urticaria Recommended by EAACI, GA2LEN, EDF, WOA
  • Table 7: Approaches To Consider When Antihistamines Fail
  • Table 8:Treatment Algorithm Recommended by the Dermato-Allergy Working Group of the Turkish Society of Dermatology And the Turkish Dermato-Immunology And Allergy Association
  • Table 9: Should Patients with Chronic Spontaneous Urticaria Be Advised To Discontinue A Medication That Is Suspected of Worsening the Disease?
  • Table 10: Total Cases of Chronic Spontaneous Urticaria in 7MM (2017-2030)
  • Table 11: Total Prevalent Cases of Chronic Spontaneous Urticaria in the United States (2017-2030)
  • Table 12: Gender-Specific Cases of Chronic Spontaneous Urticaria in the US (2017-2030)
  • Table 13: Age-Specific Cases of Chronic Spontaneous Urticaria in the US (2017-2030)
  • Table 14: Total Prevalent Cases of Chronic Spontaneous Urticaria in Germany (2017-2030)
  • Table 15: Gender-Specific Cases of Chronic Spontaneous Urticaria in Germany (2017-2030)
  • Table 16: Age-Specific Cases of Chronic Spontaneous Urticaria in Germany (2017-2030)
  • Table 17: Total Prevalent Cases of Chronic Spontaneous Urticaria in France (2017-2030)
  • Table 18: Gender-Specific Cases of Chronic Spontaneous Urticaria in France (2017-2030)
  • Table 19: Age-Specific Cases of Chronic Spontaneous Urticaria in France (2017-2030)
  • Table 20: Total Prevalent Cases of Chronic Spontaneous Urticaria in Italy (2017-2030)
  • Table 21: Gender-Specific Cases of Chronic Spontaneous Urticaria in Italy (2017-2030)
  • Table 22: Age-Specific Cases of Chronic Spontaneous Urticaria in Italy (2017-2030)
  • Table 23: Total Prevalent Cases of Chronic Spontaneous Urticaria in Spain (2017-2030)
  • Table 24: Gender-Specific Cases of Chronic Spontaneous Urticaria in Spain (2017-2030)
  • Table 25: Age-Specific Cases of Chronic Spontaneous Urticaria in Spain (2017-2030)
  • Table 26: Total Prevalent Cases of Chronic Spontaneous Urticaria in the United Kingdom (2017-2030)
  • Table 27: Gender-Specific Cases of Chronic Spontaneous Urticaria in the UK (2017-2030)
  • Table 28: Age-Specific Cases of Chronic Spontaneous Urticaria in the UK (2017-2030)
  • Table 29: Total Prevalent Cases of Chronic Spontaneous Urticaria in Japan (2017-2030)
  • Table 30: Gender-Specific Cases of Chronic Spontaneous Urticaria in Japan (2017-2030)
  • Table 31: Age-Specific Cases of Chronic Spontaneous Urticaria in Japan (2017-2030)
  • Table 32: Xolair, Clinical Trial Description, 2020
  • Table 33:Dupilumab, Clinical Trial Description, 2020
  • Table 34:Ligelizumab, Clinical Trial Description, 2020
  • Table 35: Benralizumab, Clinical Trial Description, 2020
  • Table 36: Fenebrutinib, Clinical Trial Description, 2020
  • Table 37: KPL-716, Clinical Trial Description, 2020
  • Table 38: LOU064, Clinical Trial Description, 2020
  • Table 39: UB-221, Clinical Trial Description, 2020
  • Table 40: LY3454738, Clinical Trial Description, 2020
  • Table 41: Mepolizumab, Clinical Trial Description, 2020
  • Table 42: AK002, Clinical Trial Description, 2020
  • Table 43: Market Size of Chronic Spontaneous Urticaria in 7MM in USD Million (2017-2030)
  • Table 44: US Market Size of Chronic Spontaneous Urticaria in USD Million (2017-2030)
  • Table 45: US Market Size of Chronic Spontaneous Urticaria in USD Million (2017-2030)
  • Table 46: Market Size of Chronic Spontaneous Urticaria in Germany, USD Millions (2017-2030)
  • Table 47: Germany Market Size of Chronic Spontaneous Urticaria in USD Million (2017-2030)
  • Table 48: Market Size of Chronic Spontaneous Urticaria Associated in France, USD Millions (2017-2030)
  • Table 49: France Market Size of Chronic Spontaneous Urticaria in USD Million (2017-2030)
  • Table 50: Market Size of Chronic Spontaneous Urticaria in Italy, USD Millions (2017-2030)
  • Table 51: Italy Market Size of Chronic Spontaneous Urticaria in USD Million (2017-2030)
  • Table 52: Market Size of Chronic Spontaneous Urticaria in Spain, USD Millions (2017-2030)
  • Table 53: Spain Market Size of Chronic Spontaneous Urticaria in USD Million (2017-2030)
  • Table 54: Market Size of Chronic Spontaneous Urticaria in the UK, USD Millions (2017-2030)
  • Table 55: UK Market Size of Chronic Spontaneous Urticaria in USD Million (2017-2030)
  • Table 56: Market Size of Chronic Spontaneous Urticaria in Japan, USD Millions (2017-2030)
  • Table 57: Japan Market Size of Chronic Spontaneous Urticaria in USD Million (2017-2030)

List of Figures

  • Figure 1: Epidemiology And Market Methodology
  • Figure 2: Pathophysiology of Chronic Spontaneous Urticaria
  • Figure 3: Model of the Mechanisms Underlying Chronic Urticaria
  • Figure 4: Step-Care Approach To the Treatment For Chronic Urticaria
  • Figure 5: Chronic Urticaria Treatment Guideline
  • Figure 6: Total Cases of Chronic Spontaneous Urticaria in 7MM (2017-2030)
  • Figure 7: Total Prevalent Cases of Chronic Spontaneous Urticaria in the United States (2017-2030)
  • Figure 8: Gender-Specific Cases of Chronic Spontaneous Urticaria in the US (2017-2030)
  • Figure 9: Age-Specific Cases of Chronic Spontaneous Urticaria in the US (2017-2030)
  • Figure 10: Total Prevalent Cases of Chronic Spontaneous Urticaria in Germany (2017-2030)
  • Figure 11: Gender-Specific Cases of Chronic Spontaneous Urticaria in Germany (2017-2030)
  • Figure 12: Age-Specific Cases of Chronic Spontaneous Urticaria in Germany (2017-2030)
  • Figure 13: Total Prevalent Cases of Chronic Spontaneous Urticaria in France (2017-2030)
  • Figure 14: Gender-Specific Cases of Chronic Spontaneous Urticaria in France (2017-2030)
  • Figure 15: Age-Specific Cases of Chronic Spontaneous Urticaria in France (2017-2030)
  • Figure 16: Total Prevalent Cases of Chronic Spontaneous Urticaria in Italy (2017-2030)
  • Figure 17: Gender-Specific Cases of Chronic Spontaneous Urticaria in Italy (2017-2030)
  • Figure 18: Age-Specific Cases of Chronic Spontaneous Urticaria in Italy (2017-2030)
  • Figure 19: Total Prevalent Cases of Chronic Spontaneous Urticaria in Spain (2017-2030)
  • Figure 20: Gender-Specific Cases of Chronic Spontaneous Urticaria in Spain (2017-2030)
  • Figure 21: Age-Specific Cases of Chronic Spontaneous Urticaria in Spain (2017-2030)
  • Figure 22: Total Prevalent Cases of Chronic Spontaneous Urticaria in the United Kingdom (2017-2030)
  • Figure 23: Gender-Specific Cases of Chronic Spontaneous Urticaria in the UK (2017-2030)
  • Figure 24: Age-Specific Cases of Chronic Spontaneous Urticaria in the UK (2017-2030)
  • Figure 25: Total Prevalent Cases of Chronic Spontaneous Urticaria in Japan (2017-2030)
  • Figure 26: Gender-Specific Cases of Chronic Spontaneous Urticaria in Japan (2017-2030)
  • Figure 27: Age-Specific Cases of Chronic Spontaneous Urticaria in Japan (2017-2030)
  • Figure 28: Comparison of the Jtfpp Guidelines (Representing the American Academy of Allergy, Asthma, And Immunology, And the American College of Allergy, Asthma, And Immunology) With the EAACI/GA2LEN/EDF/WAO Guidelines
  • Figure 29: Flowchart For the Management of Patients With Chronic Spontaneous Urticaria
  • Figure 30: Unmet Needs
  • Figure 31: Market Size of Chronic Spontaneous Urticaria in USD Million (2017-2030)
  • Figure 32: Market Size of Chronic Spontaneous Urticaria in the US, USD Millions (2017-2030)
  • Figure 33: Market Size of Chronic Spontaneous Urticaria in the US by therapies, USD Millions (2017-2030)
  • Figure 34: Market Size of Chronic Spontaneous Urticaria in Germany, USD Millions (2017-2030)
  • Figure 35: Market Size of Chronic Spontaneous Urticaria in Germany by therapies, USD Millions (2017-2030)
  • Figure 36: Market Size of Chronic Spontaneous Urticaria in France, USD Millions (2017-2030)
  • Figure 37: Market Size of Chronic Spontaneous Urticaria in France by therapies, USD Millions (2017-2030)
  • Figure 38: Market Size of Chronic Spontaneous Urticaria in Italy, USD Millions (2017-2030)
  • Figure 39: Market Size of Chronic Spontaneous Urticaria in Italy by therapies, USD Millions (2017-2030)
  • Figure 40: Market Size of Chronic Spontaneous Urticaria in Spain, USD Millions (2017-2030)
  • Figure 41: Market Size of Chronic Spontaneous Urticaria in Spain by therapies, USD Millions (2017-2030)
  • Figure 42: Market Size of Chronic Spontaneous Urticaria in the UK, USD Millions (2017-2030)
  • Figure 43: Market Size of Chronic Spontaneous Urticaria in the UK by therapies, USD Millions (2017-2030)
  • Figure 44: Market Size of Chronic Spontaneous Urticaria in Japan, USD Millions (2017-2030)
  • Figure 45: Market Size of Chronic Spontaneous Urticaria in Japan by therapies, USD Millions (2017-2030)
  • Figure 46: Market Drivers
  • Figure 47: Market Barriers
目次
Product Code: DIMI0998

DelveInsight's 'Chronic spontaneous urticaria (CSU) - Market Insights, Epidemiology, and Market Forecast-2030' report delivers an in-depth understanding of the Chronic spontaneous urticaria (CSU), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Chronic spontaneous urticaria (CSU) market report provides current treatment practices, emerging drugs and their market share of the individual therapies, current and forecasted Chronic spontaneous urticaria (CSU) symptoms market size from 2017 to 2030 segmented by seven major markets. The report also covers current Chronic spontaneous urticaria (CSU) symptoms treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Chronic spontaneous urticaria (CSU) Disease Understanding and Treatment Algorithm

Chronic spontaneous urticaria (CSU) Overview

Chronic urticaria is a debilitating disease that is characterized by itching and hives with or without angioedema, lasting for more than 6 weeks. Chronic urticaria might be triggered due to stimuli such as stroking or scratching the skin, exercise, emotional upset (cholinergic urticaria), cold, heat, pressure, sunlight (solar urticaria), contact with water or various chemicals (contact urticaria), or vibration. Urticaria induced, thus, is known as chronic induced urticaria (CIndU). However, more commonly chronic urticaria is endogenous and independent of any external causes. This urticaria is known as chronic spontaneous urticaria (CSU).

However, there are still few unmet needs in the understanding of disease etiology in cases where autoimmunity is ruled out. Quality of life is severely impacted in CSU patients due to unpredictability of attacks, fatigue caused by treatment side effects, and cosmetic disfigurement. Patients with CSU often exhibit psychiatric comorbidities. CSU also has a large direct and indirect economic impact due to increased healthcare cost because of continued medication to control symptoms, and frequent, often unanticipated healthcare visits. 

Chronic spontaneous urticaria (CSU) Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnosis available in the Chronic spontaneous urticaria (CSU) market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

The DelveInsight Chronic spontaneous urticaria (CSU) market report gives a thorough understanding of Chronic spontaneous urticaria (CSU) symptoms by including details such as disease definition, symptoms, causes, physiology, and diagnosis. It also provides Chronic spontaneous urticaria (CSU) symptoms of treatment algorithms and treatment guidelines for Chronic spontaneous urticaria (CSU) symptoms in the US, Europe, and Japan.

A potential diagnostic pitfall is the failure to consider a diagnosis of urticarial vasculitis in patients with lesions lasting longer than 24 h, in patients with lesions associated with pain more than with itching, and in patients with lesions resolving with pigmentary changes or scaling.

While in most cases, no diagnostic testing may be necessary, targeted laboratory testing based on clinical suspicion is appropriate. In most patients, the only screening tests that are recommended to be performed are a complete blood cell (CBC) count with differential, erythrocyte sedimentation rate (ESR) and/or C-reactive protein (CRP), liver enzymes, and thyrotropin (TSH).

The FDA has approved XOLAIR by Roche/Novartis for Chronic spontaneous urticaria (CSU) .

Chronic spontaneous urticaria (CSU) Epidemiology

The Chronic spontaneous urticaria (CSU) symptoms epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The diagnosed prevalent cases of Chronic spontaneous urticaria (CSU) is increasing in 7MM during the study period, i.e., 2017-2030.

The disease epidemiology covered in the report provides historical as well as forecasted Chronic spontaneous urticaria (CSU) symptoms epidemiology segmented as the Total Prevalent cases of Chronic spontaneous urticaria (CSU), Gender-Specific cases of Chronic spontaneous urticaria (CSU), Age-Specific cases of Chronic spontaneous urticaria (CSU). The report includes the prevalent scenario of Chronic spontaneous urticaria (CSU) symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country-wise Chronic spontaneous urticaria (CSU) Epidemiology

The epidemiology segment also provides the Chronic spontaneous urticaria (CSU) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total prevalent cases of Chronic spontaneous urticaria (CSU) associated in 7MM countries was 1,169,632 in 2017.

Chronic spontaneous urticaria (CSU) Drug Chapters

The drug chapter segment of the Chronic spontaneous urticaria (CSU) report encloses the detailed analysis of Chronic spontaneous urticaria (CSU) marketed drugs and early stage (Phase-I, II, III) pipeline drugs. It also helps to understand the Chronic spontaneous urticaria (CSU) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Chronic spontaneous urticaria (CSU) Emerging Drug

Dupilumab: Sanofi/Regeneron

Dupilumab (DUPIXENT) is a human monoclonal IgG4 antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling by specifically binding to the IL-4Rα subunit shared by the IL-4 and IL-13 receptor complexes. Dupilumab inhibits IL-4 signaling via the 'Type I' receptor and both IL-4 and IL-13 signaling through the 'Type II' receptor. Multiple cell types that express IL-4Rα (e.g., mast cells, eosinophils, macrophages, lymphocytes, epithelial cells, goblet cells) and inflammatory mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines, chemokines) are involved in inflammation. Blocking IL4Rα with dupilumab inhibits IL-4 and IL-13 cytokine-induced inflammatory responses, including the release of proinflammatory cytokines, chemokines, nitric oxide, and IgE.

Ligelizumab: Novartis Pharmaceuticals

Ligelizumab (QGE031) is a new high-affinity humanized monoclonal anti-IgE antibody that has previously shown dose-dependent and time-dependent suppression of free IgE, basophil FcεRI, basophil surface IgE, and skin-prick test responses to an allergen that was superior in extent and duration to that observed with omalizumab and aims to become first-choice biologic after antihistamine therapy.

Products detail in the report…

Chronic spontaneous urticaria (CSU) Market Outlook

The Chronic spontaneous urticaria (CSU) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted Chronic spontaneous urticaria (CSU) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Chronic spontaneous urticaria (CSU) market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Chronic spontaneous urticaria (CSU) market in 7MM is expected to grow in the study period 2017-2030.

In the United States, Joint Task Force on Practice Parameters (JTFPP) had released treatment guidelines for CSU in 2014 that recommended a stepwise management plan to help alleviate the symptoms of CSU. The first line of treatment includes monotherapy with a second-generation H1-antihistamine. If symptoms persist, a practitioner has one of several options for the 2nd line of treatment. The recommended steps include a four-fold increase in second-generation H1-antihistamine dose, the addition of an alternative second-generation H1- antihistamine, the addition of an H2-antihistamine, addition of a leukotriene receptor antagonist (LTRA), or addition of a first-generation H1-antihistamine. If the symptoms don't alleviate, the practitioner can prescribe a dose advancement of a potent antihistamine (i.e., doxepin or hydroxyzine). For those with recalcitrant disease, the organization recommends the use of Omalizumab, cyclosporine, or an alternative immunosuppressant.

Several drugs are currently in use for the treatment of chronic urticaria with evidence ranging from randomized, double-blind placebo-controlled clinical investigations to anecdotal case reports. It, therefore, becomes imperative to understand the mechanism of action of these drugs for any upcoming player in the industry.

Key Findings

This section includes a glimpse of the Chronic spontaneous urticaria (CSU) market in 7MM. The market size of Chronic spontaneous urticaria (CSU) in the seven major markets was found to be USD 1,073.3 million in 2017.

The United States Market Outlook

This section provides the total Chronic spontaneous urticaria (CSU) market size and market size by therapies in the United States.

The United States accounts for the largest market size of Chronic spontaneous urticaria (CSU) in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

EU-5 Countries: Market Outlook

The total Chronic spontaneous urticaria (CSU) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total Chronic spontaneous urticaria (CSU) market Size and market Size by therapies in Japan are also mentioned.

Chronic spontaneous urticaria (CSU) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2017-2030. The analysis covers Chronic spontaneous urticaria (CSU) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Chronic spontaneous urticaria (CSU) Pipeline Development Activities

The report provides insights into the therapeutic candidate in Phase I, II and III stage. It also analyses Chronic spontaneous urticaria (CSU) key players involved in developing targeted therapeutics.

Major players include Sanofi/Regenron, Novartis, AstraZeneca, and others.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing and patent details for Chronic spontaneous urticaria (CSU) emerging therapies.

Reimbursement Scenario in Chronic spontaneous urticaria (CSU)

Approaching reimbursement proactively can have a positive impact both during the early stages of product development and well after product launch. In the report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Xolair (Omalizumab) is approved for the treatment of antihistamine-resistant chronic spontaneous urticaria (CSU) in over 80 countries around the world. It is licensed by the European Medicines Agency of the European Union and the Food and Drug Administration of the USA. However, if the healthcare systems do not provide reimbursement in the countries where it is licensed, its accessibility for treatment is precluded by its relatively high cost. An argument of the health authorities to keep it off reimbursement lists is that CU is not a fatal disease and the regulators in countries with limited financial resources do not attach to omalizumab enough weight to override the reimbursement threshold. However, the presence of angioedema imparts to CU a higher level of importance, as the general public perceives the condition as life-threatening. Although omalizumab provides an effective treatment for CU patients with angioedema, it is all too often not available to them because of the failure of health authorities to reimburse it.

Moreover, 93% of Xolair syringe cost is covered by Medicare part D and Medicare Advantage plan. The same program covers 100% of the cost of Xolair vial. It also covers costs under Part B (Medical Insurance), which helps cover the costs of outpatient care and services. If Xolair is administered during hospital admittance or while being cared for in a skilled nursing facility, Medicare Part A would be billed first, and patients who have a Medicare Advantage plan would also receive the same Part A and Part B coverage. Still, these MA enrollees may also have additional coverage

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Chronic spontaneous urticaria (CSU) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Chronic spontaneous urticaria (CSU) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Chronic spontaneous urticaria (CSU) Market by using various Competitive Intelligence tools that includes - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of Chronic spontaneous urticaria (CSU), explaining its causes, signs and symptoms, physiology and currently available therapies
  • Comprehensive insight has been provided into the Chronic spontaneous urticaria (CSU) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Chronic spontaneous urticaria (CSU) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Chronic spontaneous urticaria (CSU) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Chronic spontaneous urticaria (CSU) market

Report Highlights:

  • In the coming years, Chronic spontaneous urticaria (CSU) market is set to change due to the rising awareness of the disease, and Favorable Environment for New Anti-infective Modalities; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Chronic spontaneous urticaria (CSU) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Chronic spontaneous urticaria (CSU). Launch of emerging therapies will significantly impact the Chronic spontaneous urticaria (CSU) market
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Chronic spontaneous urticaria (CSU)Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Chronic spontaneous urticaria (CSU) Pipeline Analysis
  • Chronic spontaneous urticaria (CSU) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Chronic spontaneous urticaria (CSU)Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Chronic spontaneous urticaria (CSU) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Chronic spontaneous urticaria (CSU)Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions:

Market Insights:

  • What were the Chronic spontaneous urticaria (CSU) Market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Chronic spontaneous urticaria (CSU) total market Size as well as market Size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Chronic spontaneous urticaria (CSU) market Size during the forecast period (2017-2030)?
  • At what CAGR, the Chronic spontaneous urticaria (CSU) market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Chronic spontaneous urticaria (CSU) market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Chronic spontaneous urticaria (CSU) market growth till 2030 and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Chronic spontaneous urticaria (CSU)?
  • What is the historical Chronic spontaneous urticaria (CSU) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Chronic spontaneous urticaria (CSU) in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Chronic spontaneous urticaria (CSU)?
  • Out of all 7MM countries, which country would have the largest prevalent population of Chronic spontaneous urticaria (CSU) during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Chronic spontaneous urticaria (CSU) along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Chronic spontaneous urticaria (CSU) in the USA, Europe, and Japan?
  • What are the Chronic spontaneous urticaria (CSU) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Chronic spontaneous urticaria (CSU)?
  • How many therapies are developed by each company for the treatment of Chronic spontaneous urticaria (CSU)?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Chronic spontaneous urticaria (CSU)?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic spontaneous urticaria (CSU) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Chronic spontaneous urticaria (CSU) and their status?
  • What are the key designations that have been granted for the emerging therapies for Chronic spontaneous urticaria (CSU)?
  • What are the global historical and forecasted market of Chronic spontaneous urticaria (CSU)?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Chronic spontaneous urticaria (CSU) market
  • To understand the future market competition in the Chronic spontaneous urticaria (CSU) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Chronic spontaneous urticaria (CSU) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Chronic spontaneous urticaria (CSU) market
  • To understand the future market competition in the Chronic spontaneous urticaria (CSU) market

Table of Contents

1 Key Insights

2 Executive summary

3 Organizations

4 Epidemiology and Market Methodology

5 Chronic Spontaneous Urticaria: Market Overview at a Glance

  • 5.1 Total Market Share (%) Distribution of Chronic Spontaneous Urticaria in 2017
  • 5.2 Total Market Share (%) Distribution of Chronic Spontaneous Urticaria in 2030

6 Chronic Spontaneous Urticaria: Market Overview at a Glance

  • 6.1 Introduction
  • 6.2 Classification
  • 6.3 Causes
  • 6.4 Signs and Symptoms
  • 6.5 Clinical Presentation
  • 6.6 Pathogenesis
  • 6.7 Diagnosis

Diagnostic Guidelines

Differential Diagnosis

  • 6.8 Treatment

Other treatments

The EAACI/GA²LEN/EDF/WAO guideline

7 Epidemiology and Patient Population

  • 7.1 Key Findings
  • 7.2 Total cases of Chronic Spontaneous Urticaria in 7MM
  • 7.3 United States
    • 7.3.1 Assumptions and Rationale
    • 7.3.2 Total Prevalent cases of Chronic Spontaneous Urticaria in the United States
    • 7.3.3 Gender-specific cases of Chronic Spontaneous Urticaria in the United States
    • 7.3.4 Age-specific cases of Chronic Spontaneous Urticaria in the United States
  • 7.4 EU5 Countries
    • 7.4.1 Assumptions and Rationale
  • 7.5 Germany
    • 7.5.1 Total Prevalent cases of Chronic Spontaneous Urticaria in Germany
    • 7.5.2 Gender-specific cases of Chronic Spontaneous Urticaria in Germany
    • 7.5.3 Age-specific cases of Chronic Spontaneous Urticaria in Germany
  • 7.6 France
    • 7.6.1 Total Prevalent cases of Chronic Spontaneous Urticaria in France
    • 7.6.2 Gender-specific cases of Chronic Spontaneous Urticaria in France
    • 7.6.3 Age-specific cases of Chronic Spontaneous Urticaria France
  • 7.7 Italy
    • 7.7.1 Total Prevalent cases of Chronic Spontaneous Urticaria in Italy
    • 7.7.2 Gender-specific cases of Chronic Spontaneous Urticaria in Italy
    • 7.7.3 Age-specific cases of Chronic Spontaneous Urticaria in Italy
  • 7.8 Spain
    • 7.8.1 Total Prevalent cases of Chronic Spontaneous Urticaria in Spain
    • 7.8.2 Gender-specific cases of Chronic Spontaneous Urticaria in Spain
    • 7.8.3 Age-specific cases of Chronic Spontaneous Urticaria Spain
  • 7.9 UK
    • 7.9.1 Total Prevalent cases of Chronic Spontaneous Urticaria in the United Kingdom
    • 7.9.2 Gender-specific cases of Chronic Spontaneous Urticaria in the United Kingdom
    • 7.9.3 Age-specific cases of Chronic Spontaneous Urticariain the United Kingdom
  • 7.10. Japan
    • 7.10.1 Assumptions and Rationale
    • 7.10.2 Total Prevalent cases of Chronic Spontaneous Urticaria in Japan
    • 7.10.3 Gender-specific cases of Chronic Spontaneous Urticaria in Japan
    • 7.10.4 Age-specific cases of Chronic Spontaneous Urticaria in Japan

8 Current treatment practices

Treatment Algorithm

9 Unmet Needs

10 Marketed drugs

  • 10.1 XOLAIR: Roche/Novartis
    • 10.1.1 Drug Description
    • 10.1.2 Regulatory Milestones
    • 10.1.3 Other Development Activities
    • 10.1.4 Clinical Development
    • 10.1.5 Safety and Efficacy
    • 10.1.6 Product Profile

11 Emerging Therapies

    • 11.1.1 Key Cross Competition
  • 11.2 Dupilumab: Sanofi/Regeneron
    • 11.2.1 Drug Description
    • 11.2.2 Other Developmental Activities
    • 11.2.3 Clinical Development
    • 11.2.4 Product Profile
  • 11.3 Ligelizumab: Novartis Pharmaceuticals
    • 11.3.1 Drug Description
    • 11.3.2 Other Developmental Activities
    • 11.3.3 Clinical Development
    • 11.3.4 Safety and Efficacy
    • 11.3.5 Product Profile
  • 11.4 Benralizumab: AstraZeneca
    • 11.4.1 Drug Description
    • 11.4.2 Other Developmental Activities
    • 11.4.3 Clinical Development
    • 11.4.4 Product Profile
  • 11.5 Fenebrutinib: Genentech, Inc.
    • 11.5.1 Drug Description
    • 11.5.2 Other Developmental Activities
    • 11.5.3 Clinical Development
    • 11.5.4 Safety and Efficacy
    • 11.5.5 Product Profile
  • 11.6 KPL-716: Kiniksa Pharmaceuticals, Ltd.
    • 11.6.1 Drug Description
    • 11.6.2 Other Developmental Activities
    • 11.6.3 Clinical Development
    • 11.6.4 Safety and Efficacy
    • 11.6.5 Product Profile
  • 11.7 LOU064: Novartis Pharmaceuticals
    • 11.7.1 Drug Description
    • 11.7.2 Other Developmental Activities
    • 11.7.3 Clinical Development
    • 11.7.4 Safety and Efficacy
    • 11.7.5 Product Profile
  • 11.8 UB-221: United BioPharma
    • 11.8.1 Drug Description
    • 11.8.2 Other Developmental Activities
    • 11.8.3 Clinical Development
    • 11.8.4 Safety and Efficacy
    • 11.8.5 Product Profile
  • 11.9 LY3454738: Eli Lilly and Company
    • 11.9.1 Drug Description
    • 11.9.2 Other Developmental Activities
    • 11.9.3 Clinical Development
    • 11.9.4 Product Profile
  • 11.1 Mepolizumab: GlaxoSmithKline
    • 11.10.1 Drug Description
    • 11.10.2 Clinical Development
    • 11.10.3 Product Profile
  • 11.11 AK002: Allakos
    • 11.11.1 Drug Description
    • 11.11.2 Other Developmental Activities
    • 11.11.3 Clinical Development
    • 11.11.4 Safety and Efficacy
    • 11.11.5 Product Profile

12 Chronic Spontaneous Urticaria: 7 Major Market Analysis

  • 12.1 Key Findings
  • 12.2 Market Size of Chronic Spontaneous Urticaria in 7MM

13 Seven Major Market Outlook

14 United States Market Size

  • 14.1 Total Market Size of Chronic Spontaneous Urticaria in the United States
  • 14.2 Total Market Size of Chronic Spontaneous Urticaria by Therapies in the United States
  • 14.3 Germany
    • 14.3.1 Total market size of Chronic Spontaneous Urticaria in Germany
    • 14.3.2 Total market size of Chronic Spontaneous Urticaria by Therapies in Germany
  • 14.4 France
    • 14.4.1 Total market size of Chronic Spontaneous Urticaria in France
    • 14.4.2 Total Market size of Chronic Spontaneous Urticaria by Therapies in France
  • 14.5 Italy
    • 14.5.1 Total market size of Chronic Spontaneous Urticaria in Italy
    • 14.5.2 Total Market size of Chronic Spontaneous Urticaria by Therapies in Italy
  • 14.6 Spain
    • 14.6.1 Total Market Size of Chronic Spontaneous Urticaria in Spain
    • 14.6.2 Total market size of Chronic Spontaneous Urticaria by Therapies in Spain
  • 14.7 United Kingdom
    • 14.7.1 Total market size of Chronic Spontaneous Urticaria in the United Kingdom
    • 14.7.2 Total market size of Chronic Spontaneous Urticaria by Therapies in the UK
  • 14.8 Japan
    • 14.8.1 Total market size of Chronic Spontaneous Urticaria in Japan
    • 14.8.2 Total market size of Chronic Spontaneous Urticaria by Therapies in Japan

15 Market Drivers

16 Market Barriers

17 SWOT Analysis

18 Market Access

Reimbursement

19 Case Study

  • 19.1 A Case Report on Successful and Safe Treatment of Chronic Spontaneous Urticaria with Omalizumab in a Woman During Two Consecutive Pregnancies
  • 19.2 A Case Report on Vitamin D Treatment for Chronic Urticaria
  • 19.3 Management Problems in Severe Chronic Inducible Urticaria: A Case Report
  • 19.4 A Case Report on the Resolution of Chronic Urticaria Following Treatment of Odontogenic Infections

20 KOL Views

21 Appendix

  • 21.1 Report Methodology

22 DelveInsight Capabilities

23 Disclaimer

24 About DelveInsight

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.